CFS Investment Advisory Services’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.87M Buy
4,838
+97
+2% +$99.1K 0.39% 58
2026
Q1
$4.39M Sell
4,741
-131
-3% -$133K 0.3% 69
2025
Q4
$5.24M Buy
4,872
+479
+11% +$458K 0.38% 64
2025
Q3
$3.63M Sell
4,393
-133
-3% -$99K 0.27% 74
2025
Q2
$3.53M Buy
4,526
+238
+6% +$185K 0.29% 73
2025
Q1
$3.54M Buy
4,288
+51
+1% +$42.4K 0.32% 71
2024
Q4
$3.27M Buy
4,237
+41
+1% +$33.9K 0.29% 70
2024
Q3
$3.72M Sell
4,196
-2,734
-39% -$2.46M 0.31% 63
2024
Q2
$6.27M Buy
+6,930
New +$5.54M 0.51% 43
2023
Q3
Sell
-2,714
Closed -$1.27M 209
2023
Q2
$1.27M Buy
+2,714
New +$1.14M 0.16% 106
2022
Q3
Sell
-1,638
Closed -$531K 310
2022
Q2
$531K Sell
1,638
-545,901
-100% -$164M 0.08% 161
2022
Q1
$2K Buy
547,539
+545,927
+33,866% +$140M 0.01% 284
2021
Q4
$396K Hold
1,612
0.05% 176
2021
Q3
$372K Buy
+1,612
New +$398K 0.05% 170

Other funds holding LLY

CFS Investment Advisory Services's LLY Position: Q2 2026 in Review

CFS Investment Advisory Services increased its Eli Lilly (LLY) stake by 2% in Q2 2026, buying an estimated $99.1K and bringing the position to 4,838 shares worth $5.87M. The position accounts for 0.39% of the portfolio, ranked #58.

CFS Investment Advisory Services first reported a position in LLY in Q3 2021 and has held it in 14 quarters since. The position peaked at $6.27M in Q2 2024. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • CFS Investment Advisory Services held 4,838 shares of Eli Lilly worth $5.87M as of Q2 2026.
  • CFS Investment Advisory Services bought 97 Eli Lilly shares in Q2 2026, an estimated $99.1K.
  • Eli Lilly made up 0.39% of CFS Investment Advisory Services's portfolio in Q2 2026, its #58 holding.
  • CFS Investment Advisory Services first reported a position in Eli Lilly in Q3 2021 and has held it in 14 quarters since.
  • CFS Investment Advisory Services's Eli Lilly position peaked at $6.27M in Q2 2024.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on CFS Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.